Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells 10,028 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille Bedrosian sold 10,028 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.40, for a total transaction of $324,907.20. Following the completion of the transaction, the insider owned 278,064 shares in the company, valued at approximately $9,009,273.60. This trade represents a 3.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Amylyx Pharmaceuticals Stock Up 6.4%

Shares of AMLX stock traded up $2.02 on Monday, reaching $33.64. 1,816,910 shares of the stock were exchanged, compared to its average volume of 1,682,389. The stock has a market cap of $3.75 billion, a P/E ratio of -23.52 and a beta of -0.13. The firm has a 50 day moving average of $25.69 and a two-hundred day moving average of $18.87. Amylyx Pharmaceuticals, Inc. has a 1-year low of $10.83 and a 1-year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AMLX. Robert W. Baird lifted their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. Mizuho increased their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. HC Wainwright raised their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Finally, Citigroup boosted their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $36.50.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth about $158,534,000. Jupiter Topco LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at about $94,014,000. Commodore Capital LP raised its holdings in shares of Amylyx Pharmaceuticals by 38.6% during the 4th quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock valued at $68,252,000 after buying an additional 1,574,522 shares during the period. California State Teachers Retirement System raised its holdings in shares of Amylyx Pharmaceuticals by 2,106.9% during the 2nd quarter. California State Teachers Retirement System now owns 1,434,501 shares of the company’s stock valued at $25,764,000 after buying an additional 1,369,499 shares during the period. Finally, Siren L.L.C. purchased a new stake in shares of Amylyx Pharmaceuticals during the 1st quarter valued at about $17,097,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

About Amylyx Pharmaceuticals